Cancer Drug Resistance

cdr

Search

Hot Keywords

Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Emerging RAS-directed therapies for cancer

Michael Conroy, ... Austin G. Duffy

Review|Published on: 8 Apr 2021
History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications

Franco Muggia, Andrea Bonetti

Review|Published on: 18 Mar 2021

Submit a Manuscript

Review Articles See more

The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas

Anudeep Yekula, ... Leonora Balaj

Published on: 19 Mar 2021
Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer

Natasha Rinne, ... Paula Cunnea

Published on: 14 Apr 2021
The implication of liquid biopsies to predict chemoresistance in pancreatic cancer

Elisabetta Pietri, ... Ingrid Garajová

Published on: 14 Apr 2021
Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancer

Wing-Kee Lee, Thévenod Frank

Published on: 9 Mar 2021

Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer

Ganeshkumar Rajendran, ... Benjamin L. Woolbright

Published on: 19 Mar 2021
Key genes and drug delivery systems to improve the efficiency of chemotherapy

Zally Torres-Martinez, ... Kai Griebenow

Published on: 19 Mar 2021
P53-regulated autophagy and its impact on drug resistance and cell fate

Daeun Shim, ... Carl G. Maki

Published on: 19 Mar 2021
Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

Anna Ulldemolins, ... Simo Schwartz Jr

video

Published on: 19 Mar 2021

Original Articles See more

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma

Jean-Marie Michot, ... Vincent Ribrag

Published on: 26 Mar 2021

Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells

Christophe Deben, ... Patrick Pauwels

Published on: 19 Mar 2021
Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging

Chelvam Venkatesh, ... Philip S. Low

Published on: 19 Mar 2021
Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance

Federica Bessone, ... Roberta Cavalli

Published on: 19 Mar 2021
A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma

Issa Ismail Issa, ... Karen Dybkær

video

Published on: 19 Mar 2021

EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer

Kevin J. Lee, ... Natalie R. Gassman

Published on: 5 Dec 2020
Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance

Federica Bessone, ... Roberta Cavalli

Published on: 19 Mar 2021
ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome

Wanqi Wang, ... Carmela Ricciardelli

video

Published on: 25 Feb 2021

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression

Derek A. Franklin, ... Justin M. Balko

Published on: 25 Apr 2020
Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel

Eiman Mukhtar, ... Paraskevi Giannakakou

Published on: 17 Apr 2020

Other Types of Articles See more

UCP2 - Taking the heat out of P-glycoprotein?

Richard Callaghan, Mary Board

Opinion|Published on: 8 Jan 2021

Overcoming drug resistance in glioblastoma: new options in sight?

Joanna Kopecka, Chiara Riganti

Editorial|Published on: 13 Jan 2021
Application of liquid biopsy for prognostic status of cancers and drug response

Dario Marchetti

Editorial|Published on: 3 Nov 2020
Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms?

Carl Christofer Juhlin

Commentary|Published on: 3 Nov 2020
Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?

Thales Paulo Batista, Graziela Zibetti Dal Molin

video

Commentary|Published on: 10 Jul 2020

Most Cited Papers In Last Two Years See more

Drug resistance and combating drug resistance in cancer

Xuan Wang, ... Xiaozhuo Chen

Review|Published on: 19 Jun 2019

MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution

Natarajan Aravindan, ... Sheeja Aravindan

Review|Published on: 19 Dec 2019
Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors

Ratnakar Singh, ... Michael J. Spinella

Review|Published on: 19 Sep 2019

The role of exosomal long non-coding RNAs in cancer drug resistance

Mireia Cruz De los Santos, ... George A. Calin

Review|Published on: 19 Dec 2019
Cancer stem cells in neuroblastoma therapy resistance

Natarajan Aravindan, ... Sheeja Aravindan

Review|Published on: 19 Dec 2019
New insights into acquired endocrine resistance of breast cancer

Ping Fan, V. Craig Jordan

Review|Published on: 19 Jun 2019

Ongoing Special Issues See more

Special Issue Ebooks See more

About The Journal

ISSN

2578-532X (Online)

Publisher

OAE Publishing Inc.

Article Processing Charge

OAE Publishing Inc. undertakes Article Processing Charge for authors
Editor-in-Chief

Godefridus J. Peters

Publishing Model

Gold Open Access

Copyright

Copyright is retained by authors
Publication Frequency

Quarterly

Journal Data Analysis

Total publications: 211

Total article views: 592,859

Total article downloads: 83,426

Membership

COPE

Cancer Drug Resistance is a member of the Committee on Publication Ethics (COPE) and fully adhere to its Code of Conduct and to its Best Practice Guidelines.
STM

Cancer Drug Resistance (cdr) is a member of and subscribes to the principles of STM. Authors of cdr can reuse a certain quantity of article contents from the chargeable publications of other STM members for free in their submissions to cdr.
ORCID

Cancer Drug Resistance (cdr) is a member of ORCID and MESAs system has been connected with ORCID. After submissions to cdr are published, they will be automatically synchronized to the authors' ORCID accounts if the authors have connected their MESAs accounts with ORCID accounts. cdr's reviewers can choose to synchronize their review records to their ORCID accounts when filling in review reports.
Crossref

Cancer Drug Resistance is a member of Crossref, which makes research outputs easy to find, cite, link, assess, and reuse.
iThenticate

All submissions to Cancer Drug Resistance are checked for plagiarism by iThenticate.
Check for updates

All published articles in Cancer Drug Resistance are enriched with a record of the current article status.

Open Archives

Portico

All published articles will be preserved here permanently:
https://www.portico.org/

Partners